Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

APR launches new Corporate Website, changes Business Model

APR announces today the launch of its new Corporate Website reflecting a clear strategic change in the APR Business Model and competitive positioning in order to better compete in the very rapidly changing Healthcare market. The company repositioning is also reflected in its revised logo.

15 Jun 2010

AMA recommends classification of e-cigarettes as drug delivery devices

New policy adopted today by the American Medical Association (AMA) recommends that electronic cigarettes (e-cigarettes) be classified as drug delivery devices, subject to the same FDA regulations as all other drug delivery devices. Additional policy adopted supports prohibiting the sale of e-cigarettes that are not FDA approved.

15 Jun 2010

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.

15 Jun 2010

Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010

Celsion Corporation announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation Oncology Annual Meeting. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer.

14 Jun 2010

Intellipharmaceutics International files Protonix ANDA with FDA

Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

14 Jun 2010

3M Health Care launches new foam adhesive dressings for acute and chronic wounds

3M Health Care today announced the introduction of a full line of new, innovative Tegaderm™ High Performance Foam Adhesive Dressings. In clinical and laboratory tests, these new adhesive foam wound dressings outperform other leading foam adhesive dressings in managing the full range of low- to high-moisture conditions that can be present in chronic and acute wounds.

14 Jun 2010

Delcath Systems to host conference call to update shareholders about recent progress

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.

11 Jun 2010

I-Flow reaches agreement with Apex, Zone to resolve patent infringement, trade secret litigation

I-Flow Corporation, a subsidiary of Kimberly-Clark Corporation, is pleased to announce that it has reached an agreement resolving patent infringement and trade secret litigation against Apex Medical Technologies, Inc. and Zone Medical, LLC effective June 10, 2010.

11 Jun 2010

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

10 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

MonoSol Rx, APR expand film formulation development collaboration

MonoSol Rx, the developer of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, and APR Applied Pharma Research s.a. ("APR") announced today an expansion of their relationship to identify and develop film formulations of prescription drug products beyond ondansetron and donepezil to include zolmitriptan. Zolmitriptan is currently commercially available for the acute treatment of migraine headache in adults, and facing initial patent expirations in 2012.

10 Jun 2010

Enavail to build new cGMP facility in Abilene Life Sciences Accelerator

Enavail, LLC, a particle engineering company founded on pioneering drug delivery research from the University of Texas at Austin, announced today the company's plans for the construction of a new state-of-the-art current Good Manufacturing Practices (cGMP) facility in the Abilene Life Sciences Accelerator (ALSA). The Enavail facility will be the first of its kind in the West Texas region.

9 Jun 2010

Clinical guidelines for UC emergency medicine physicians

Though guidelines for best treatment practices are common, they are only partially effective without standardized, routine exposure to them in clinical practice, according to a study conducted by University of Cincinnati emergency medicine researchers.

9 Jun 2010

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Impax Laboratories, Inc. today announced that it has reached agreement with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle pending U.S. litigation with regard to the production and sale of generic formulations of OPANA ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

DSM, which created and manufactures Dyneema Purity, the world's strongest Medical grade fiber, today announced agreements with Biomedical Structures, Cortland Company and Secant Medical. These companies' experience in processing Dyneema Purity fiber in biomedical textile structures offers medical device companies the ability to use various constructions of Dyneema Purity, including the recently launched Dyneema Purity BLUE, in commercial medical devices.

9 Jun 2010

BD to sell certain assets of Medical segment

BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it has signed agreements to sell certain assets of its BD Medical segment, including the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms of the Medical Surgical Systems unit.

From BD (Becton, Dickinson and Company) 8 Jun 2010

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

8 Jun 2010

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today reported preliminary outcomes and trends from the ongoing Phase III pivotal study of Generex Oral-lyn, the Company's proprietary oral insulin spray product.

7 Jun 2010

Drug Delivery News and Research

Further Reading

APR launches new Corporate Website, changes Business Model

AMA recommends classification of e-cigarettes as drug delivery devices

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010

Intellipharmaceutics International files Protonix ANDA with FDA

3M Health Care launches new foam adhesive dressings for acute and chronic wounds

Delcath Systems to host conference call to update shareholders about recent progress

I-Flow reaches agreement with Apex, Zone to resolve patent infringement, trade secret litigation

FDA grants Collegium Fast Track designation for COL-172 opioid formulation

Nativis awarded patents in Japan, China, India for drug signal technology

MonoSol Rx, APR expand film formulation development collaboration

Enavail to build new cGMP facility in Abilene Life Sciences Accelerator

Clinical guidelines for UC emergency medicine physicians

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

Endo, Penwest announce settlement of OPANA ER litigation with Impax

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

BD to sell certain assets of Medical segment

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News